Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DAiLY Clear all
Completed Phase 1 Interventional

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

NCT07242469
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
MK-1403 + additive coformulation, Placebo + additive coformulation
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Anaheim, California • Chula Vista, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 22, 2026, 5:21 PM EDT
Completed No phase listed Observational

A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder

NCT04300569
View directory record Official record
Conditions
Irregular Sleep Wake Rhythm Disorder
Interventions
Non-interventional
Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Costa Mesa, California • San Diego, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 22, 2026, 5:21 PM EDT
Not listed Phase 1 Interventional

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

NCT03217669
View directory record Official record
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer (NSCLC)
Interventions
Epacadostat, sirolimus
Drug
Lead sponsor
Chao Huang
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Fairway, Kansas • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Not applicable Interventional Results available

The Use of the GlideScope Ranger in Pediatric Critical Care Transport

NCT01054183
View directory record Official record
Conditions
Respiratory Failure
Interventions
GlideScope Ranger Intubation, Direct Laryngoscopy
Device
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Up to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2015 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Phase 3 Interventional

Risperidone and Suicidality in Major Depressive Disorder

NCT00167154
View directory record Official record
Conditions
Depression
Interventions
Risperidone and placebo comparator
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

NCT01907854
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, sitagliptin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
58
States / cities
Phoenix, Arizona • Tucson, Arizona • Escondido, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 22, 2026, 5:21 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

ProGo Menopause Wellbeing Study

NCT07611305
View directory record Official record
Conditions
Menopause Related Conditions
Interventions
Salmon protein hydrolysate (SPH) powder formulated into a tablet format, Microcrystalline Cellulose
Dietary Supplement
Lead sponsor
Hofseth Biocare ASA
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Cangrelor Ticagrelor Transition Study

NCT01766466
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
cangrelor, Ticagrelor
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Not applicable Interventional

KU Alternate Meal Energy Level Study

NCT03696966
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Portion-Controlled Meals, Low-Calorie Diet, Intermittent Very-Low Calorie Diet
Dietary Supplement · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

NCT00549666
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Lurasidone 40 mg, Placebo 40 mg, Ortho Tri-Cyclen
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Sep 22, 2026, 5:21 PM EDT
Active, not recruiting Phase 1 Interventional

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

NCT07021066
View directory record Official record
Conditions
Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer, Other Solid Tumors
Interventions
BL-M05D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of AG-348 in Healthy Volunteers

NCT02149966
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AG-348, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Phase 2 Interventional

A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

NCT05630066
View directory record Official record
Conditions
Angelman Syndrome
Interventions
Alogabat
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 22, 2026, 5:21 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

NCT06325566
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Rexlemestrocel-L + HA mixture, Saline
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects

NCT03376802
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Orlando, Florida • Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury

NCT02962102
View directory record Official record
Conditions
Critically Ill, Acute Kidney Injury
Interventions
Calcifediol, Calcitriol, Placebos
Drug
Lead sponsor
David Leaf
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Not applicable Interventional

Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device

NCT04008537
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Pelvis, Cancer of Abdomen, Cancer of Thorax
Interventions
Ring gantry kV-CBCT combined with linear accelerator
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Phase 3 Interventional Results available

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

NCT01516879
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

NCT02703779
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Granulocyte colony-stimulating factor (G-CSF), Mozobil
Drug
Lead sponsor
Siddhartha Ganguly
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 22, 2026, 5:21 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT03842696
View directory record Official record
Conditions
Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease
Interventions
Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine), Methotrexate, Mycophenolate Mofetil (MMF), Cyclophosphamide
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
3 Years to 39 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 22, 2026, 5:21 PM EDT
Withdrawn Phase 2 Interventional

Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants

NCT02420496
View directory record Official record
Conditions
Cholestasis, Liver Disease
Interventions
Enteral fish oil, Ursodeoxycholic Acid, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
14 Days to 24 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer

NCT00601796
View directory record Official record
Conditions
Lung Cancer
Interventions
Vaccine Treatment, Cyclophosphamide, All-trans retinoic acid (ATRA)
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Sep 22, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer

NCT00003496
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Sep 22, 2026, 5:21 PM EDT
Completed Not applicable Interventional Results available

Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease

NCT03405662
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Vielight Neuro Gamma, Sham Vielight Neuro Gamma
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 22, 2026, 5:21 PM EDT